Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ETH-155008 in Relapsed/Refractory AML and NHL
NCT05758610Phase 1Recruiting
- Sponsor
- Shengke Pharmaceuticals
- Start
- Nov 2022
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ETH-155008 in acute myeloid leukemia (AML) and Non-Hodgkin lymphoma (NHL), sponsored by Shengke Pharmaceuticals. Primary endpoints: Incidence and severity of adverse events, Dose Limiting Toxicity and 1 more. Started Nov 2022; status: recruiting.
02
Drugs
ETH-155008
03
Conditions
acute myeloid leukemia (AML)Non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT05758610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05758610.